Rituximab-induced remission of autoimmune hypophysitis and primary immune thrombocytopenia in a patient with autoimmune polyendocrine syndrome type 4

References

• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-99
   PubMed Web of Science ®Google Scholar
• Schreckinger M, Francis T, Rajah G, et al. Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg 2012;116:1318-23
   PubMed Web of Science ®Google Scholar
• De Bellis A, Pane E, Bellastella G, et al. Italian Autoimmune Hypophysitis Network Study. Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. Clin Endocrinol (Oxf) 2011;75:361-6
   PubMed Web of Science ®Google Scholar
• De Bellis A, Salerno M, Conte M, et al. Antipituitary antibodies recognizing growth hormone (GH)-producing cells in children with idiopathic GH deficiency and in children with idiopathic short stature. J Clin Endocrinol Metab 2006;91:2484-9
   PubMedGoogle Scholar
• De Bellis A, Colella C, Bellastella G, et al. Late primary autoimmune hypothyroidism in a patient with postdelivery autoimmune hypopituitarism associated with antibodies to growth hormone and prolactin-secreting cells. Thyroid 2013;23:1037-41
   PubMedGoogle Scholar
• De Bellis A, Sinisi AA, Conte M, et al. Antipituitary antibodies against gonadotropin-secreting cells in adult male patients with apparently idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007;92:604-7
   PubMedGoogle Scholar
• De Bellis A, Bizzarro A, Conte M, et al. Antipituitary antibodies in adults with apparently idiopathic growth hormone deficiency and in adults with autoimmune endocrine diseases. J Clin Endocrinol Metab 2003;88:650-4
   PubMed Web of Science ®Google Scholar
• Betterle C, Presotto F. Autoimmune polyendocrine syndromes (APS) or multiple autoimmune syndrome (MAS). In: Walker S, Jara LJ, editors. Handbook of systemic autoimmune diseases. Endocrine manifestations of systemic autoimmune diseases. Elsevier; Amsterdam, NL: 2008. 9: p. 135-48
   Google Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33
   PubMed Web of Science ®Google Scholar
• Fabris F, Scandellari R, Randi ML, et al. Attempt to improve the diagnosis of immune thrombocytopenia by combined use of two different platelet autoantibodies assays (PAIgG and MACE). Haematologica 2002;87:1046-52
   PubMedGoogle Scholar
• Fabris F, Scandellari R, Ruzzon E, et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004;103:4562-4
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Hamasaki A, Okamoto M. A case of suspected lymphocytic hypophysitis and organizing pneumonia during maintenance therapy for autoimmune pancreatitis associated with autoimmune thrombocytopenia. Endocr J 2006;53:563-6
   PubMed Web of Science ®Google Scholar
• De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab 2005;19:67-84
   PubMed Web of Science ®Google Scholar
• De Bellis A, Bizzarro A, Bellastella A. Pituitary autoimmunity. In: Eisenbarth G, editor, Immunoendocrinology: scientific and clinical aspects, contemporary endocrinology. Humana Press; New York, USA: 2011. p. 547-67
   Google Scholar
• Bellastella A, Bizzarro A, Coronella C, et al. Lymphocytic hypophysitis: a rare or underestimated disease? Eur J Endocrinol 2003;149:363-76
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82
   PubMed Web of Science ®Google Scholar
• El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009;130:252-8
   PubMed Web of Science ®Google Scholar
• Yu L, Herold K, Krause-Steinrauf H, et al. Rituximab selectively suppresses specific islet antibiodies. Diabetes 2011;60:2560-5
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52
   PubMed Web of Science ®Google Scholar
• Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189-95
   PubMed Web of Science ®Google Scholar
• Constant S, Schweitzer N, West J, et al. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 1995;155:3734-41
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pinto D, Moreno J. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol 2005;35:1097-105
   PubMedGoogle Scholar
• Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280-5
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73
   PubMed Web of Science ®Google Scholar
• Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005;26:599-614
   PubMed Web of Science ®Google Scholar
• Caturegli P, Lupi I, Landek-Saldago M, et al. Pituitary autoimmunity: 30 years later. Autoimmun Rev 2008;7:631-7
   PubMed Web of Science ®Google Scholar
• Smith CJ, Bensing S, Burns C, et al. Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis: immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays. Eur J Endocrinol 2012;166:391-8
   PubMedGoogle Scholar